Additionally, CAR-T cells expressing CXCR1 or CXCR2, which bind IL-8—a chemokine implicated in tumorigenesis within the tumor microenvironment—have demonstrated efficacy in targeting prostate, ovarian, melanoma and colon cancer cells. This evidence concerns the gene CXCR2 and melanoma.